Anhui Anke Biotechnology (SHE:300009) received approval from the Chinese drug administration to conduct clinical trials into a growth hormone drug, according to a Shenzhen Stock Exchange filing on Thursday.
The injection will be tested in babies considered small-for-gestational-age (SGA), a disease that affects infants' growth and development, the biotech company said.
The company's shares closed 3% higher on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。